Single Dose Of RSV Vaccine Effective For Three Seasons Among Older Adults, Study Finds

Infectious Disease Advisor (6/28, Nye) reported, “A single dose of the Ad26. RSV.preF–RSV prefusion (pre-F) protein vaccine was found to sustain high protective efficacy across 3 respiratory syncytial virus (RSV) seasons among older adults, according to study results published in The Lancet Infectious Diseases.” In the study, “over seasons 2 and 3 combined, RSV-associated LRTI was observed in 4 (0.2%) vaccine recipients and 17 (0.8%) placebo recipients, translating to a vaccine efficacy of 71.6% (95% CI, 26.9-94.2). Across all 3 seasons, RSV-associated LRTI was observed in 10 (0.4%) vaccine recipients and 47 (1.7%) placebo recipients, translating to a vaccine efficacy of 78.7% (95% CI, 57.3-90.4).”